FDA has granted orphan drug designation to the drug-device startup Bionaut Labs (Los Angeles) for the company’s lead therapeutic program, BNL-101, for the local treatment of malignant gliomas. BNL-101 is a drug-device combination that brings together remote-controllable microscale robotics and the chemotherapy agent doxorubicin. In March, the startup received $20 million in funding from Khosla Ventures. […]